Company / Operating Margin
Krystal Biotech, Inc. Operating Margin History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
41.4%
FY2025
5-year range
-216.2% / 41.4%
FY2023-FY2025
Trend
+83.2%
vs FY2024
Sector context
#7 of 136
Health Care
What the data says
Among 136 Health Care companies, Krystal Biotech, Inc. is in the top 5% for operating margin. Improved from -216.2% to 41.4% over the past 2 years.
Based on SEC 10-K filings.
41.4% in FY2025. Top quartile in the Health Care sector.
Improved from -216.2% to 41.4% over the past 2 years.
Health Care sector context is included.
Operating Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Top 5% in Health CareTop 5% of 136This company 41.4% Sector average -778.9%
▼
+105.3% above sector average
Key checks
Key Insights
- In FY2025, operating margin increased 83.2% year-over-year.
- Currently 820.4pp above the Health Care sector average.
Company context
Key Data Points
- Altman Z-Score 5.66 (safe zone, above 2.9 threshold)
- Strong profit margin: 30.7%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 41.4% | +83.2% |
| FY2024 | 22.6% | +110.5% |
| FY2023 | -216.2% | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026